122 related articles for article (PubMed ID: 11226516)
1. Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
Bahng H; Lee JH; Ahn JH; Lee JH; Lee JS; Kim SH; Kim WK; Lee KH
Leuk Res; 2001 Mar; 25(3):213-6. PubMed ID: 11226516
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
5. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
[TBL] [Abstract][Full Text] [Related]
6. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
10. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
11. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
[TBL] [Abstract][Full Text] [Related]
12. The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Friedenberg WR; Miller HJ; Marx JJ; Schloesser LL; Reding DJ; Mazza JJ; Hocking WG; Mercier RJ; Raich PC; Cassileth PA
Am J Clin Oncol; 1995 Apr; 18(2):105-10. PubMed ID: 7900701
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
18. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
19. Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L; Hasenclever D; Krahl R; Pönisch W; Herold M; Pasold R; Fiedler F; Dölken G; Kämpfe D; Schmoll HJ; Súbert R; Kubel M; Niederwieser D; Helbig W;
Leuk Lymphoma; 2002 Feb; 43(2):265-74. PubMed ID: 11999557
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
